Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance

Biomark Med. 2019 May;13(7):535-543. doi: 10.2217/bmm-2018-0382. Epub 2019 May 29.

Abstract

Aim: To investigate the expression of long intergenic noncoding RNA 00515 (LINC00515) in high-grade serous ovarian cancer (HGSOC) and its potential correlation with platinum resistance. Patients & methods: Expression of LINC00515 in HGSOC (n = 115) and normal (n = 19) tissues was detected via quantitative real-time PCR (qRT-PCR). We further explored the statistical significance of the relationship between LINC00515 expression and platinum resistance in HGSOC. Results: LINC00515 was gradually downregulated in the order of normal > platinum-sensitive > platinum-resistant tissue (p < 0.05). Results demonstrated that LINC00515 downregulation was correlated with platinum resistance and relapse-free survival (RFS) of HGSOC (p < 0.05). Conclusion: LINC00515 downregulation is correlated with HGSOC development, platinum resistance and RFS, supporting its utility as a potential biomarker to predict platinum resistance and prognosis of RFS.

Keywords: LINC00515; biomarkers; cancer recurrence; high-grade serous ovarian cancer; long intergenic non-coding RNA; platinum-based chemotherapy resistance; qRT-PCR analysis; relapse-free survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Down-Regulation / drug effects*
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Grading
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology*
  • Platinum / pharmacology*
  • RNA, Long Noncoding / genetics*

Substances

  • RNA, Long Noncoding
  • Platinum